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Abstract
Skeletal muscle is rarely a site of malignant metastasis; the molecular and cellular basis for this rarity is not understood. We
report that myogenic cells exert pronounced effects upon co-culture with metastatic melanoma (B16-F10) or carcinoma
(LLC1) cells including conversion to the myogenic lineage in vitro and in vivo, as well as inhibition of melanin production in
melanoma cells coupled with cytotoxic and cytostatic effects. No effect is seen with non-tumorigenic cells. Tumor
suppression assays reveal that the muscle-mediated tumor suppressor effects do not generate resistant clones but function
through the down-regulation of the transcription factor MiTF, a master regulator of melanocyte development and a
melanoma oncogene. Our findings point to skeletal muscle as a source of therapeutic agents in the treatment of metastatic
cancers.
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Introduction
Understanding the cellular and molecular mechanisms leading
to metastasis is of key importance for targeting metastatic cells
since no efficient method to block metastasis exists [1,2,3,4]. The
metastatic conversion of a tumor cell involves cell-autonomous
changes which alter cellular cross-talk in the tissue environment.
Interactions between tumor cells and the host organ rely on similar
mechanisms governing interactions during embryogenesis [5,6,7].
The host organ microenvironment is critical in regulating
metastatic tumor growth [4,8,9,10]. Most tissues are subject to
secondary tumor growth with the striking exception of skeletal
muscle in which malignant metastases are very rare [11,12,13,14].
This is particularly surprising because skeletal muscle comprises
,40 percent of total body mass and is highly vascularized
[11,13,14,15]. Willis and colleagues reported a frequency of 0.8%
of intramuscular metastasis in autopsied cases [16]. A retrospective
study over a 30-year period revealed that only 1.6% of soft tissue
sarcomas (muscle) examined was of metastatic origin [12]. The
origins of these metastases were mostly primary lung carcinomas
(70%) and malignant melanomas (17%) [12]. The rarity of
malignant metastases in skeletal muscle led Paget to propose the
‘‘seed and soil hypothesis’’ over 100 years ago, namely that
metastasis is a function not only of the type of tumor (‘‘seed’’) but
also of the host tissue (‘‘soil’’) [17].
The cellular and molecular mechanisms underlying the rarity of
secondary metastasis in skeletal muscle have remained elusive.
Several studies have linked muscle activity with inhibition of tumor
growth [18,19,20]. The influence of b-adrenergic receptors on
muscle vasculature and blood flow may pose a limiting factor for
metastatic tumor growth [21]. Angiogenesis is required for all
tumor growth [22]. Production of lactic acid by tumor cells
promotes angiogenesis through activation of vascular endothelial
growth factor (VEGF) [23,24]. Skeletal muscle produces high
levels of lactic acid suggesting that muscle vasculature blood may
not respond to additional lactic acid secretion by invasive tumor
cells [25]. Over-production of lactic acid is detrimental for tumor
development [26]. Several groups have shown that muscle
conditioned media exert a cytostatic effect upon tumor cells
[27,28]. Adenosine and other low molecular weight factors were
suggested to be responsible for the inhibition of tumor cell growth
through the A3 adenosine receptor, however, adenosine depleted
conditioned media still retained a cytostatic effect [29,30].
In this study, we make use of the highly metastatic murine
melanoma B16F-10 [31,32] as well as the Lewis Lung carcinoma
[33] cell lines, within the context of a skeletal muscle microen-
vironment in vitro and in vivo. In man, malignant melanoma
accounts for only 4% of all dermatologic cancers but is responsible
for 80% of skin cancer mortality because of its high metastatic rate
(American cancer society, 2003). Several molecules implicated in
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phisms in MC1R, a gene involved in melanin production, increase
the risk of melanoma following exposure to UV light [35]. In
melanoma patients, mutations, deletions and genomic amplifica-
tions of genes involved in cell cycle control, apoptotic pathways,
and in oncogenes such as CDKN2A, PTEN, AKT, N-RAS, and
BRAF occur at different rates [36,37,38,39]. Altered expression of
adhesion molecules such as cadherins, integrins, and the WNTs
are implicated in the metastatic spreading of melanoma [40,41].
Finally, MiTF, a key transcription factor in survival, maintenance
and differentiation of melanocytes is detected in most malignant
melanomas and the gene is amplified in 10 to 20% of cases of
metastasis [42,43,44,45].
In this study, we show that interactions between melanoma cells
with either primary or established myogenic cell lines lead to
specific changes in melanoma cell behavior, including inhibition of
melanin pigment production. In addition, we observe that GFP
labeled melanoma and Luis Lung carcinoma cells fuse to form
myotubes when co-cultured with myoblasts. Injection of GFP-
labeled melanoma cells into uninjured or regenerating skeletal
muscle results in GFP positive myofibers indicating that these cells
are recruited into muscle fibers. Serum free muscle-conditioned
media exerts a cytostatic and cytotoxic effect upon metastatic cells
but has little effect upon non-metastatic cells suggesting that
muscle secreted factors are not general cell growth inhibitors.
Surprisingly, tumor suppression assays fail to generate ‘muscle-
resistant’ melanoma tumor cells such that cells subject to multiple
rounds of selection remain sensitive to the growth suppression
effects exerted by muscle, and is accompanied by down-regulation
of the transcription factor MiTF. Furthermore, MiTF downreg-
ulation is dependent upon cell contact and myogenic cell density in
the co-culture. These findings suggest a mechanism whereby
skeletal muscle inhibits secondary metastasis by the secretion of
factors as well as by cell-to-cell interactions that hijack metastatic
cells, leading to myogenic conversion and reduced growth by
acting through signaling mechanisms not normally involved in
tumor suppression.
Results
Metastatic Melanoma Cells Fail to Invade and Colonize
Skeletal Muscle
We injected 5610
5 B16-F10 melanoma cells into the tail vein or
the peritoneum of C57/Bl6 syngeneic mice and analyzed for the
presence of tumors 3 weeks after injection. The B16-F10
melanoma cell line produces melanin-expressing tumors allowing
for easy identification of tumors in dissected tissues. Three weeks
following tail vein injection of B16-F10 cells, we observed the
presence of black pigmented growths in all organs examined
including lung, liver, spleen, intestine, and heart (Table 1). In
contrast, no metastases were observed in skeletal muscles of the
limbs and diaphragm, which were examined in detail (Table 1).
We observed that if cells were injected intraperitoneally (IP) versus
the tail vein, tumor frequency shifted among tissues (i.e. all animals
showed intestinal tumors following IP injections versus 4 out of 12
following tail vein injections) (Table 1). Nonetheless, regardless of
route of injection, no tumors were ever observed in skeletal muscle
tissues.
Previous studies have demonstrated that the B16-F10 cell line
displays preferential distribution to the lung following tail vein
injection [46,47], therefore we tested the B16-F0 subclone that has
a wider metastatic range of tissues and does not preferentially
invade the lung [32]. Three weeks following tail vein injection of
5610
5 B16-F0, we observed tumors in the lung, liver, intestine,
heart, and bones (Table 1). As for the F10 cell line, no tumors were
detected in skeletal muscle despite their presence in the adjacent
bones. Only few isolated melanin-secreting B16-F0 cells were
detected in the epimysium closely associated with the Tibialis
Anterior (TA) muscle of one animal, consistent with the low
incidence of skeletal muscle metastatic tumor invasion and growth.
Myogenic Cells Inhibit B16-F10 Melanoma Cells
Differentiation In Vitro
To follow melanoma tumor behavior at the cellular level, we
generated GFP expressing B16-F10 cells (B16-GFP) and chal-
lenged them directly in culture with a variety of cell types
including skeletal muscle cells. We co-cultured B16-GFP cells over
a range of cell ratios ranging from 1:1 to 1:400 with fibroblasts
(10T1/2), liver cells (BNL.CL2), and murine skeletal muscle
(C2C12) cell lines. Due to the inherently high proliferative rate of
melanoma cells, the optimal ratio of tumor cells to other cell lines
was determined to be 1:100 to allow for proper visualization of the
two cell types at the end of the experiment. Once co-cultured cells
were confluent, serum levels were decreased to induce myogenic
differentiation (Differentiation Media, DM). We note that even
though DM was used to provoke myogenic differentiation, all
combinations of cell types were subjected to the identical
treatment allowing for a direct comparison of outcomes. Following
4–6 days in DM, B16-GFP differentiate into melanin producing
cells. When B16-GFP are co-cultured with fibroblasts (10T1/2),
Table 1. Distribution of B16 melanoma tumour cells in mouse organs following different delivery routes.
Injection route Nu Lung Liver Spleen Bone Heart Skeletal muscle Intestine
TA Other muscles
c
iv Tail (B16F10)1 2 1 2 5 6 0 9
a 00 4
Ip (B16F10)6 0 1 1 0 0 0 0 6
iv Tail (B16F0)4 4 2 0 3 4
b 0
d 01
aTumors in the endocardium 6/9; tumors in the myocardium 3/9.
bTumors in the endocardium 3/4; tumors in the myocardium 1/4.
cFore and hind limb muscles + diaphragm were examined in detail.
dFew isolated melanin-secreting B16-F0 cells were found associated with muscle surface of a single individual. No evidence of tumor invasion was observed.
iv: intra-venous 5610
5 cells injected.
ip: intraperitoneal 1610
3 cells injected.
TA: Tibialis anterior.
doi:10.1371/journal.pone.0009299.t001
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GFP cells retain their ability to secrete black melanin pigments
(Figure 1A,B). When co-cultured with liver cells (BNL.CL2), the
B16-GFP melanoma cells segregate presumably due to different
cellular adhesion properties, forming islands of GFP+ cells
expressing melanin distributed among the BNL.CL2 liver cells
(Figure 1A). In contrast, when B16-GFP cells are co-cultured with
myogenic cells (C2C12), they remain closely associated with
differentiating myogenic cells, and acquire an elongated morphol-
ogy (Figure 1A). In addition to this striking change in cell shape,
we observed that none of the B16-GFP cells secrete melanin
(Figure 1A). A similar outcome was observed when melanoma cells
and myogenic cells where co-cultured at a ratio of 1:1 (data not
shown). We note that B16-GFP cells are present at a lower number
following co-culture with myoblasts as compared to co-cultures
with other cell types (Figure 1A) suggesting either a lower rate of
proliferation and/or increased cell death. Quantification of the
number of melanin secreting cells in the different co-culture
conditions reveals an absence of melanin positive cells (1.86 cells
60.35/field) in co-cultures with myogenic C2C12, while in
fibroblast and liver cell co-cultures, we observe a mean value of
41366 and 333612.96 melanin positive cells/field respectively
(Figure 1B). We conclude that skeletal muscle cells inhibit
melanoma cell differentiation (measured by melanin expression).
Metastatic Cancer Cells Cultured with Skeletal Muscle
Cells Participate to the Myogenic Program
The elongated morphology observed in melanoma cells co-
cultured with myogenic cells suggested that B16 cells ‘‘fuse with
myogenic cells and might’’ undergo myogenic conversion. We
therefore examined the expression of skeletal muscle specific
markers (MyoD and Myosin heavy chain (MF20)) in co-cultures of
B16-GFP cells with either C2C12, or primary murine myoblasts
using immunofluorescence. As shown in Figure 2, we can identify
myotubes (multinucleated cells) positive for GFP and MF20,
indicating that GFP melanoma cells have fused with the
Figure 1. Myogenic cells inhibit B16-F10 melanoma cells differentiation in vitro. A) Photomicrographs of GFP expressing melanoma cells
(B16) grown alone or in co-culture with myogenic cells (C2C12), fibroblasts (10T1/2), or liver cells (BNL.CL2). We note an inhibition of melanin
production in B16 co-cultured with C2C12 as well as a change in their morphology. Scale bar =50 mm. B) Quantification of the number of melanin
secreting B16 cells grown alone, or in co-culture with fibroblasts, liver cells, or myogenic cells reveals that myogenic cells completely abolish melanin
production in B16 cells.
doi:10.1371/journal.pone.0009299.g001
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myotubes in co-cultures of GFP-labeled melanoma cells and
C2C12 cells are positive for MF20 and GFP (Figures 2A, 2B). In
addition, MyoD, a muscle transcription factor expressed in
myoblasts and early myotubes, was detected in GFP positive
myotubes (9.6% of the total number of myotubes) (Figure 2B).
This fusion process was specific to melanoma cells and did not
occur in co-cultures of GFP labeled fibroblasts with myogenic
C2C12 cells (Figure 2B). To test whether the ability of myogenic
cells to fuse with metastatic cells was limited to melanoma, we
extended our analyses to the Luis Lung carcinoma line [33]. We
therefore generated GFP expressing Luis Lung Carcinoma cells
Figure 2. Murine and human muscle cells recruit tumor cells in the myogenic program. A) Representative photomicrographs of GFP
expressing B16 cells (green) grown and differentiated in co-culture with either C2C12 mouse myogenic cell line or mouse primary myoblasts and
stained for myosin heavy chain (MF20, red). GFP labeled melanoma cells fuse with the C2C12 cells forming chimeric green myotubes, which are
positive for MF20. Nuclei were visualized by DAPI staining (blue). Scale bar =20 mm. B) Quantification of GFP expressing myotubes positive for either
MyoD or Myosin heavy chain (MF20), from co-cultures of GFP-labeled melanoma cells (B16-GFP) or GFP-labeled Luis Lung Carcinoma cells (LLC1-GFP)
with mouse myogenic cells (C2C12), human primary myogenic cells (CHQ), or fibroblasts (10T1/2) immunostained as shown in panel A. Only murine
and human muscle cells can recruit Luis Lung Carcinoma (LLC1-GFP) and melanoma(B16-GFP) cells into the myogenic program. This phenotypic
conversion is specific to cancer cells and does not occur in co-cultures of GFP labeled fibroblasts with myogenic C2C12 cells. Values represent the
mean percentage of at least 3 independent experiments 6 SEM. C) Expression of murine Desmin and MyoD transcripts in co-cultures of B16-GFP/
CHQ; C2C12/CHQ and CHQ cells alone(RT-PCR). The graph shows the expression levels of Desmin and MyoD transcripts in co-cultures relative to the
expression in C2C12/CHQ co-cultures. Experiments were performed in triplicates.
doi:10.1371/journal.pone.0009299.g002
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for the GFP-B16 cells, the LLC1-GFP cells acquired an elongated
morphology and ultimately fused with C2C12 cells giving rise to
chimeric green myotubes (Figure S1) that express MyoD (8%) and
MF20 (11%) (Figure 2B). No MyoD nor MF20 expression was
detected in co-cultures of B16-GFP or LLC1-GFP with 10T1/2
fibroblasts (Figure 2B). Lastly, B16-GFP and LLC1-GFP cells fuse
with human primary myoblasts (CHQ) giving rise to chimeric
green myotubes that express MyoD (5%) and MF20 (9.1%)
(Figure 2B). We explored a number of different conditions
including testing whether B16-GFP cells fuse with C2C12 cells
previously differentiated into myotubes. As observed in coculture
with myoblasts, B16-GFP cells plated onto fully differentiated
myotubes fuse with myotubes and do not secrete melanin (data not
shown). In order to determine if the B16-GFP melanoma cells are
reprogrammed and convert to the myogenic lineage upon fusion,
we co-cultured murine B16-GFP melanoma cells with human
primary myoblasts (CHQ) in a 1/500 ratio. Using RT-PCR, we
searched for the presence of murine muscle specific transcripts and
detected the presence of murine Desmin (an early myogenic
marker) suggesting the phenotypic conversion of the melanoma
cells into a myogenic lineage upon fusion (Figure 2C). No murine
MyoD transcripts were detected indicating that the conversion is
probably driven by myogenic transcription factors from neigh-
boring human nuclei within the same cytoplasm. Semi-quantita-
tive analysis revealed that the expression levels of murine Desmin
reached an average of 46%612.9 in B16-GFP/CHQ co-cultures
as compared to murine C2C12/CHQ co-cultures (Figure 2C). No
detectable levels of murine Desmin transcripts were present in
10T1/2 fibroblasts/CHQ co-cultures (not shown). Finally, the
absence of murine transcripts (Desmin and MyoD) in CHQ
cultures alone indicates the specificity of the primers to amplify
only murine transcripts (Figure 2C).
B16-GFP Melanoma Cells Undergo Myogenic Conversion
In Vivo
To determine whether melanoma cells display a similar
myogenic conversion in vivo, we injected 1610
3 B16-GFP cells
into injured and non-injured Tibialis Anterior muscles of C57/Bl6
syngeneic mice. Mice were sacrificed at 2 and 3 weeks following
B16-GFP injection and selected muscles (soleus, gastrocnemius,
and tibialis anterior) from injected legs as well as lung, bone,
spleen, liver, heart were collected, analyzed for the presence of
tumors, and frozen for immunofluorescence analysis. Three weeks
following B16-GFP injection, we detected small melanoma
nodules that displayed well-defined boundaries and did not invade
the surrounding muscles such as the gastrocnemius and the soleus
(data not shown). No melanoma cells were detected in any of the
organs examined (lung, bone, spleen, liver and heart). To identify
melanoma cell fate, we analyzed injured and non-injured muscles
2 weeks following injection of B16-GFP cells. Muscle tissue is
composed of multinucleate myofibers surrounded by a basal
lamina (extra-cellular matrix), which delineate the fibers from the
interstitium consisting of vessels and connective tissue [48]. In the
case of injured muscle, newly regenerated myofibers can be
recognized by the presence of centrally located myonuclei [49].
Frozen sections were immunostained for laminin to visualize the
basal lamina of the fibers. Following injection of B16-GFP
melanoma cells, GFP+ myofibers were detected in both injured
(Figure 3A-C) and non-injured (Figure 3E-G) muscles. In most
cases, the GFP+ fibers are in close proximity with the melanoma
cells (Figure 3). The basal lamina of these fibers often appeared
irregular, suggesting that the melanoma cells disrupt the extra-
cellular matrix of the myofiber or that neighboring muscle cells
respond to the presence of melanoma cells and alter their ECM
composition (Figure 3). Consistent with our macroscopic observa-
tions, there was a tightly defined boundary at the tumor-muscle
border (Figure 3F,G arrowheads). In non-injured muscles, the
GFP+ myofibers have peripheral nuclei (unlike muscle fibers
undergoing regeneration), revealing that GFP+ melanoma cells
fuse to pre-existing fibers and that regeneration is not a
prerequisite condition for tumor cells participation into myofibers.
No green fibers were observed in controlateral control injured and
non-injured muscles (Figure 3D and 3H), which received an
injection of PBS (see Materials and Methods).
To assess whether metastatic cells can cross the vessel barrier
into muscle tissue in vivo, 1610
5 B16-GFP cells were injected into
the femoral artery of C57/Bl6 syngeneic mice. To prevent
significant circulation of cells to other organs, the femoral artery
was clamped during and just after the injections as described in
Material and Methods. Two weeks after intrafemoral injection, we
note GFP+ myofibers next to melanoma in both uninjured
(Figure 3J) and injured muscle (Figure 3K), as seen with the
intramuscular injections as well as cells under the the muscle fascia
(Figure 3I). Longitudinal sections of intramuscularly injected TA
muscles show that GFP is homogeneously distributed along the
length of the muscle fiber (Figure 3L). Taken together, these data
suggest that tumor cells are able to cross the vessel barrier and that
skeletal muscle is able to ‘‘recruit’’ melanoma cells into the
myogenic program and exert an inhibitory effect on tumor growth
and invasion in vivo.
Conditioned Media from C2C12 Myogenic Cells Exert an
Apoptotic Effect on Tumorigenic Cells
Co-culture experiments with B16-GFP or LLC1-GFP and
differentiating C2C12 cells gave rise to cultures which appeared
to contain less tumor cells (Figure 1A and Figure S1). It is well
accepted that acquired resistance to apoptotic and/or growth arrest
signals plays a major role in tumor progression [50,51]. To
determine if diffusible factors secreted by muscle cells induce cell
cycle arrest and/or cell death in B16 cells, we collected serum-free
conditioned media from C2C12 muscle cultures (CMC2C12)a n d
from 10T1/2 fibroblast cultures (CM10T1/2). We tested conditioned
media on B16 cells as well as C2C12 myoblasts and 10T1/2
fibroblasts and monitored cell morphology, number, and cell cycle
status using propidium iodide uptake followed by FACs analysis.
10T1/2 fibroblasts grown in CM10T1/2 or CMC2C12 display robust
growth and do not display overt changes in morphology (Figure 4A,
upper panels). Furthermore, we did not observe significant
differences in cell cycle profiles of 10T1/2 fibroblasts exposed to
CM10T1/2 or CMC2C12 (Figure 4A, lower panels). After one day in
fibroblasts conditioned media (CM10T1/2) 0,6% of the 10T1/2
fibroblasts were apoptotic versus 2,5% of apoptotic cells in cultures
incubated in conditioned media from myogenic cells (CMC2C12)
(Figure 4C).Thepercentage ofapoptoticfibroblastcellsdidnotvary
3 days after incubation in both conditioned media (Figure 4C).
When B16 melanomacellswereincubatedfor1dayinCM10T1/2or
in CMC2C12, we do not observe a significant change in the cell
morphology (data not shown) nor in cell cycle profile (Figure 4C).
There were no changes in the cell morphology of B16 cells grown
for 3 days in fibroblast conditioned media (Figure 4B, upper panels)
and the percentage of apoptotic B16 melanoma cells did not vary
significantly between 1 day or 3 days of exposure to CM10T1/2
(Figure 4B and C). In contrast, B16 melanoma cells incubated in
(CMC2C12) for 3 days appear refractile and rounded (Figure 4B,
upper panels). In addition, the cell cycle profiles show a marked
increase in the percentage of apoptotic cells (40,5% versus 59,5% of
cycling cells) (Figure 4B, C). The apoptotic effect of muscle
Muscle Inhibits Metastases
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we obtained similar results with Lewis-Lung carcinoma cells (Figure
S2) indicating a specific effect by muscle conditioned media upon at
least 2 metastatic cell types. As expected, CM10T1/2 did not have
any apoptotic effect on the Lewis-Lung carcinoma cells (Figure S2).
Muscle Conditioned Media Induces Reversible Changes
in B16 Melanoma Cells
To assess whether metastatic cells acquire resistance to the
muscle-mediated effects, we performed tumor suppression assays
in which B16 cells were grown for prolonged periods in muscle
conditioned media. Such assays typically result in the killing of
most of the cells followed by the growth of resistant colonies. B16
cells were grown in the presence of CMC2C12, which induced
pronounced cell death by 3 days and we observe that by 4–7 days,
colonies of B16 melanoma cells appear. These colonies were
allowed to recover in normal media and then subjected to two
additional rounds of selection under identical conditions. The
number of surviving cells for each selection cycle was determined.
A pronounced decrease (83%) in the number of B16 melanoma
cells was observed during the first round of selection with
CMC2C12 (S1), 71% for the second round (S2) and 62% for the
third round (S3) (Figure 5A,B, green lines). An average of 10 to 15
cells/field were observed after 3 days of selection in CMC2C12
Figure 3. B16 melanoma cells fuse with muscle fibers in vivo. A-H) Confocal micrographs of representative cross sections of TA muscles,
showing fusion of GFP-labeled B16 melanoma cells with injured (A-C) and non-injured (F-H) muscles, 2 weeks after intramuscular injection. The basal
lamina is identified by the red laminin immunostaining. Nuclei are visualized by DAPI staining (blue). We note GFP+ myofibers with centrally located
nuclei (A-C asterisk), characteristic of muscle fibers undergoing regeneration. Green, GFP+ myofibers are observed in non-regenerating muscle as
well, indicating that GFP+ melanoma cells fuse to pre-existing fibers. In both cases, we note GFP positive fibers within the site of injection (A),
adjacent to the tumor (F,G), as well as in areas devoid of tumor (B,C,E). At the periphery of the tumor we note a well defined boundary between the
tumor and the muscle tissue (arrowheads). No green fibers were detectable in the controlateral control injured and non-injured muscles injected with
PBS (D,H). I-K) Representative cross sections of TA muscles, 2 weeks after intrafemoral artery injection of GFP-labeled B16 melanoma cells. L) Confocal
micrographs of a representative longitudinal section of TA muscle, showing homogenous expression of GFP along the muscle fiber length, 2 weeks
after intramuscular injection of GFP-labeled B16 melanoma cells. Scale bar =20 mm.
doi:10.1371/journal.pone.0009299.g003
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small colonies (Figure 5A,B). Indeed, after 4 days of selection, the
number of B16 melanoma cells that had resumed growth
increased and reached 76% of the original number of cells at
the time of selection. We conclude that while the B16 cells are
growth suppressed in the presence of CMC2C12, they do not
acquire a permanent change in cell behavior after multiple rounds
of selection. B16 cells grown in (CM10T1/2) or DMEM alone
continue to proliferate and the number of cells increases on
average by 23% and 29% (Figure 5A,B) respectively during the 3
cycles of selection, confirming the absence of an apoptotic effect of
serum free CM10T1/2 or DMEM on the B16 melanoma cells.
Furthermore, these results point to a specificity of the muscle
conditioned media on tumorigenic cells. After 3 days of selection, a
statistically significant difference was observed in the proliferation
rate of cells grown in CMC2C12 as compared to cells grown in
either CM10T1/2 (p=0.013) or serum free DMEM (p=0.006). In
contrast, there was no significant difference in the proliferation
rate of melanoma cell grown in serum free DMEM as compared to
melanoma cells grown in CM10T1/2. Selected B16 melanoma cells
transferred to serum containing growth media (GM) resume
normal behavior, including melanin secretion, further confirming
that the inhibitory effects exerted by muscle cells upon B16 cells is
completely reversible.
Figure 4. Apoptotic effect of the conditioned media from C2C12 muscle cells on B16 melanoma cells. A,B, upper panels) Phase contrast
photomicrographs of 10T1/2 fibroblasts (A) and B16-F10 melanoma cells (B) cultured in serum free conditioned media from 10T1/2 fibroblasts
(CM10T1/2) or in serum free conditioned media from muscle cells (CMC2C12) for 3 days. After 3 days in CMC2C12, B16 melanoma cells are less numerous
and appear rounded and refractive (B). Scale bar =50 mm. A,B, lower panels) Propidium iodide flow cytometry cell cycle analysis of 10T1/2 fibroblasts
(A) and B16 melanoma cells (B) in the different culture media. The bars indicate the fraction of apoptotic cells for each experimental condition. The
cell cycle profile is notably changed in melanoma cells incubated for 3 days in muscle cells conditioned media. C) Percentage of apoptotic versus
cycling cells of 10T1/2 fibroblasts (blue bars) and B16-F10 melanoma cells (green bars) cultured in either serum free conditioned media from 10T1/2
fibroblast (CM10T1/2) or C2C12 muscle cells (CMC2C12) after 1 and 3 days post incubation (dpi). Only B16F10 melanoma cells exhibit a significantly high
level of apoptotic cells (40.5%62.5) when cultured in CMC2C12 for 3 days (p#0.05). Values represent the mean % 6 SEM of 3 independent
experiments.
doi:10.1371/journal.pone.0009299.g004
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PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9299Figure 5. Emergence of reversibly resistant B16 melanoma colonies in CMC2C12 during a multiple selection process. A) Representative
photomicrographs of B16 melanoma cells grown in CMC2C12,C M 10T1/2, or serum free media (DMEM). CMC2C12 induces pronounced cell death by 3
days. However, 4 days after selection colonies of B16 melanoma cells start to appear. CM10T1/2 and DMEM do not affect the number of melanoma
cells. Scale bar =40 mm. B) Schematic representation of the number of B16F10 melanoma cells/field after 1, 3 and 4 days of 3 successive rounds of
selection in CMC2C12(green), CM10T1/2 (violet) and DMEM (red lines). In the first round of selection (S1) the number of melanoma cells grown in
CMC2C12 (green line- circle) sharply decreases at Day 3. Cells grown in CM10T1/2 (violet) or in serum free DMEM (red) continue to proliferate. At 4 day
the number of cells grown in CMC2C12 reaches 76% of the original number of cells at time of selection. The same trend is observed for the subsequent
rounds of selection (S2,S3). For each time point, values represent a mean of 3 independent experiments. S1: Selection1; S2: Selection2; S3: Selection3.
CM10T1/2 (violet lines) (*; p=0.013). DMEM (red lines) (**; p=0.006).
doi:10.1371/journal.pone.0009299.g005
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Inhibition and Induce MiTF Downregulation on Parental
and Selected B16-GFP Melanoma Cells
To analyze the contribution of cell-cell interactions to the
muscle-mediated inhibitory effect upon metastatic cells, parental
B16-GFP cells or B16-GFP that had undergone selection for 3
days in CMC2C12 were grown with C2C12 myogenic cells. C2C12
cells were seeded at 2 different densities (low and high) and
parental or selected B16-GFP were plated at a ratio of 1/400
allowing for a clonal distribution of the melanoma cells and the
number of B16-GFP cells per colony was counted on day 4. High
density of muscle cell cultures results in a sharp decrease in the
number of parental B16-GFP cells. As shown in Figure 6A, the
mean value of 276 cells/colony obtained with parental B16-GFP
cells in co-culture with C2C12 cells plated at low density
significantly decreases to 99 cells/colony in co-cultures with
high-density C2C12 myogenic cells (Figure 6A, p,0.05). Selected
B16-GFP cells showed significantly lower mean values of 25 and
12 cells/colony in low and high-density C2C12 co-cultures
respectively (Figure 6A, p,0.05). These results demonstrate a
density-dependant inhibitory effect of myogenic cells upon
melanoma cell growth. Furthermore, the inhibitory effect of the
myogenic cells on the selected B16 melanoma cells is stronger than
that of the parental cells under similar conditions (25 versus 276
cells/colony at low density C2C12; 12 versus 99 cells/colony at
high density C2C12. Figure 6A). In all cases melanin production
was not observed.
MiTF is a transcription factor required for melanocyte lineage
survival and melanin production; MiTF is also implicated in
melanoma progression and metastasis [52,53,54]. Analyses of
MiTF reveal expression in both parental and selected B16-GFP
cells grown with low density C2C12 as well as low density 10T1/2
fibroblasts (Figure 6B, left panels). In contrast, MiTF expression is
not detectable in parental and selected melanoma cells cultured
with C2C12 cells plated at high density (Figure 6B, top right
panels). This effect is specific to muscle cells, as it is not observed in
10T1/2 fibroblasts/B16-GFP co-cultures (Figure 6B, lower right
panels). Taken together, these data suggest that the inhibitory
effect of muscle cells upon melanoma cells is density-dependent
and targets MiTF expression.
Discussion
The rarity of secondary metatastasis in skeletal muscle has
provoked a number of investigations and hypotheses for over 100
years. One simple explanation for the apparent resistance of
skeletal muscle to secondary tumors was proposed by Ewing [55]
which suggests that the probability for the deposition of blood-
born tumor cells reflects circulatory patterns and hemodynamics.
Consistent with this view, we find that B16-F10 cells have a
preferential distribution in the lung following tail vein injection
(and see [31,32]). However, while we observe that 100% of tumor
cell-injected mice developed lung tumors, and 30–50% showed
tumors in the liver, spleen and intestine, we consistently find no
tumor appearance in skeletal muscle. Given the high number of
cells injected into the circulation exceeding the number of
circulating metastatic cells in a metastatic incident, mechanical
models only provide a partial explanation. Results presented here
lend support to the ‘‘seed and soil’’ hypothesis proposed by S.
Paget (1889) in which specific interactions between the tumor
cell and host environment favor or inhibit growth and metastasis
[17]. In addition to our findings, it has been demonstrated that
B16-F10 cells have a preferential cell adhesion to lung tissue
[56,57]. Furthermore, organ-selectivity is maintained in ectopi-
cally grafted tissues. Dunn Osteosarcoma is known to favor
the lung as a target for metastasis and will target ectopic
(subcutaneous) lung grafts whereas subcutaneous skeletal muscle
is not targeted [58]. We observed that intra-peritoneal injection
of the B16-F10 cells led to a preferential tumor growth in the
intestine, suggesting direct dissemination of tumor cells. A similar
distribution of tumor cells is observed when we injected the B16-
F0 (versus the B16-F10) melanoma cell line with a wider
metastatic range [32]. We found that tumor growths were
evident in the bone but not in surrounding skeletal muscle despite
close proximity of the two tissues. It has been amply
demonstrated that many stem cells are able to target skeletal
muscle consistent with there being no mechanical barrier in
skeletal muscle to circulating cells [59,60]. We note that for the
B16-F0 and F10 melanoma lines, a high incidence of tumor
growth is found in the heart (75%) indicating that the tumor
suppressive properties of skeletal muscle are not shared by cardiac
muscle. Taken together, we propose skeletal muscle has a local
tumor suppressive effect.
B16-F10 cells display two distinctive features in response to co-
culturing with myogenic cells: the absence of melanin production
and the acquisition of a myotube-like morphology. It was
reported that the presence of cutaneous hypopigmentation
favorably influences the prognosis and survival rate of patients
with malignant melanoma [61,62]. In vitro, a correlation
between expression of the secreted factor MIA (a key molecule
involved in progression and metastasis of malignant melanoma)
and decreased melanogenesis was shown in the human
melanoma cell line HMB2 [53,63]. However, similar invasive
and migratory characteristics were found when comparing low or
high melanin producing B16 melanoma sublines suggesting that
melanin production and invasive behavior may not be tightly
linked [64]. In our study, the inhibition of melanin production in
the B16 melanoma cells in co-culture with myogenic cells could
reflect a lower degree of differentiation and thus a higher
predisposition or plasticity allowing for myogenic conversion of
the melanoma cells. Staining of the myotube-like elongated B16-
GFP cells with myogenic markers (MyoD and MF20) confirmed
the fusion and incorporation of melanoma cells into myotubes.
About 10% of myotubes in our co-cultures contained fused
melanoma cells as evidenced by the presence of GFP suggesting
that only a subpopulation of the melanoma cells undergo
conversion. A similar frequency of GFP+ myotubes was observed
in co-cultures of myogenic cells with the carcinoma cell line
(LLC1) suggesting a general mechanism whereby myogenic cells
inhibit expansion of metastatic tumors in skeletal muscle.
Furthermore, upon fusion with human myogenic cells (CHQ),
the B16-GFP cells express early murine myogenic markers such
as Desmin suggesting the reprogramming and conversion of
melanoma cells into myogenic cells. The absence of murine
MyoD transcripts indicates that the conversion is probably driven
by myogenic transcription factors from neighboring human
nuclei within the same cytoplasm. In addition, B16-GFP cells
were able to fuse with the nascent or the pre-existing myofibers
when directly or intra-arterially injected into injured or uninjured
TA muscle. Taken together, these data suggest that a subpop-
ulation of B16 cells have stem-cell properties with enhanced
phenotypic plasticity allowing their fusion and conversion to the
myogenic lineage. Emerging evidence indicates that tumor cells
contain a subpopulation of cells showing embryonic-like plasticity
that correlates with invasive capacity [65,66,67,68,69,70].
Several studies demonstrated that melanoma cells differentiate
into endothelial-like cells leading to enhanced tumor growth
[68,71,72].
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PLoS ONE | www.plosone.org 9 February 2010 | Volume 5 | Issue 2 | e9299Figure 6. Myogenic cells exert density dependant growth inhibition and induce MiTF downregulation on parental and selected
B16-GFP melanoma cells. A) Distribution of the number of cells per colony of either parental or selected B16-GFP melanoma cells, grown with
C2C12 cells plated at low and high density. Muscle cells inhibit growth of melanoma cells. Cells previously exposed to muscle conditioned media are
more sensitive to this effect. The inhibition is dependent on the density of muscle cell. The black lines represent the mean values of 3 independent
experiments: 276 cells/colony for parental B16-GFP in low-density C2C12; 99 cells/colony for parental B16-GFP in high-density C2C12; 25 cells/colony
for selected B16-GFP in low-density C2C12; 12 cells/colony for selected B16-GFP in high-density C2C12. B) Left Panels: parental (B16-GFP, green) or
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ronment contributes to the partial loss of tumorigenicity through
a phenotypic conversion into muscle. A similar reprogramming of
multipotent melanoma cells was observed following their
transplantation into embryonic neural crest [73,74]. Specifically,
when melanoma cells are placed into the embryonic neural crest,
they followed the migratory pathways of surrounding crest cells
and did not form tumors [73,74]. It is possible that the melanoma
cells that undergo phenotypic conversion into muscle possess
stem cell characteristics. Interestingly, the stem cell marker,
CD133 is found to be expressed in many different cancer types
including human melanomas and is believed to be a characteristic
of a cancer stem cell [75,76,77,78,79]. Furthermore, when
delivered through the vascular network, mesenchimal stem cells
and CD133+ cells can cross the endothelial barrier and will form
muscle suggesting shared properties with metastatic cells [60,80].
Adhesion molecules such as NCAM are expressed in melanoma
cells as well as in muscle satellite cells, which may facilitate
tumor-myoblast fusion [81,82,83]. Finally, the Pax3 transcription
factor is expressed in both myogenic and melanoma cells and
plays a key role in cell migration during embryonic development
and specification of the muscle stem cell niche [84,85]. Taken
together, we propose that metastatic cells and migratory stem
cells share an overlapping set of cellular characteristics which
predisposes metastatic cells to respond to tissue-specific local clues
that act upon cell fate. In this context, skeletal muscle exerts a
dominant effect upon metastatic cells, recruiting them into the
myogenic program resulting in the observed rarity of metastatic
tumors in skeletal muscle of humans [11,12,13,14].
The effect of muscle cells upon metastatic cells can be explained
in part by the presence of diffusible signals secreted by muscle into
the local milieu that act specifically on metastatic cells and not on
non-metastatic cells. Muscle conditioned media exerts a specific
apoptotic effect upon metastatic cells with pronounced melanoma
cell death after 3 days, whereas no effect was observed upon non
metastatic cells. Previous investigations have identified several
muscle-produced factors capable of inhibiting metastatic growth
including adenosine and unidentified low molecular weight factors
acting through the A3 adenosine receptor [29,30], however,
adenosine mediated inhibition of cell growth was also found in
non-metastatic cells [86,87,88]. In our study, we find that
conditioned media from muscle had no effect on proliferation
and death of normal cells revealing a specificity for metastatic cells
and potential promise as an avenue of research to identify
therapeutic approaches to metastatic cancers.
While a single factor may underlie the muscle-mediated effects
on metastatic cells that we report here, our data support a
mechanism whereby muscle exerts 3 specific inhibitory effects
upon metastatic cells which are 1) cellular recruitment into the
myogenic lineage, 2) a paracrine-mediated cytostatic and 3)
paracrine-mediated cytotoxic response. It is well established that
prolonged exposure of tumor cells to cytostatic/cytotoxic stimuli
lead to selection of genetically resistant clones [89,90,91]. Clonal
selection of resistant metastatic cancer cells constitutes a major
problem for clinical treatments in which therapeutic options
become exhausted over time. If such a process occurs in muscle,
we would predict the eventual appearance of tumors in skeletal
muscle. When we performed tumor suppressor assays in which
B16 cells are grown for prolonged and repeated rounds in muscle
conditioned media, about 20% of the cells ultimately resume
growth but do not acquire permanent changes in behavior.
Consistent with this proposal, B16 cells display a marked down-
regulation of MiTF which is dependent upon cell density and
cell-cell contact. A similar observation was made in a porcine
model of spontaneously regressing melanoma in which MiTF was
noted to be significantly downregulated during the regressive
phase of the melanoma and upregulated during the progressive
phase suggesting a central role for this protein in melanoma
biology [92]. MiTF also controls the expression of Tbx2 and
CDK2, which are involved in melanoma proliferation and
suppression of senescence [93,94,95], in addition to anti-
apoptotic genes such as Bcl2 and ML-IAP [96,97]. Taken
together, we conclude that conditioned media-mediated apoptosis
and contact-dependant growth inhibition are two key mecha-
nisms accounting for the effect of skeletal muscle on metastatic
cells. The fusion and the subsequent myogenic reprogramming
observed in vitro and in vivo, remain limited and specific to a
subpopulation of B16 melanoma cells and is probably related to
enhanced phenotypic plasticity. Finally, downregulation of MiTF
and subsequent induction of apoptosis and inhibition of cell
growth may underlie the limited expansion of melanoma cells
when grown in a skeletal muscle microenvironment. Defining the
muscle mediated signaling pathways that lead to MiTF
downregulation will be of key importance in the identification
of the factors responsible for muscle mediated tumor growth
inhibition.
Materials and Methods
Ethics Statement
All work with mice was carried out in adherence to French
Government guidelines as well as those of the NIH and was
approved by the Pierre et Marie Curie University.
Mice and In Vivo Experiments
Experiments were performed in 8 to 12 weeks old female
C57BL/6J mice (Janvier, France). For intravenous (tail vein),
intra-arterial (Text S1) and intraperitoneal injections, 5610
5 B16-
F10-GFP or B16-F0-GFP cells were injected in 200 ml of PBS.
Muscles and other organs were harvested 3 weeks after injection,
analyzed for the presence of B16 melanoma cells and snap frozen
in liquid nitrogen. Skeletal muscle regeneration was induced by a
freeze-crush injury of the left tibialis anterior (TA), as previously
described [98]. 24 hours post-injury, B16-F10-GFP melanoma
cells (1610
3 cells in 30 ml PBS) were injected into the left injured
and the right uninjured TA muscles. Control TA muscles were
injected with PBS.
Cell Culture
C2C12 myoblasts, B16-F10 and B16-F0 melanoma cells, Luis
Lung Carcinoma (LLC1), BNL CL.2 liver cells and 10T1/2
fibroblasts were grown in DMEM supplemented with 20% Fetal
selected (selected B16- GFP, green) melanoma cells expressing GFP grown with low density C2C12 or 10T1/2 fibroblasts and immunostained for MiTF
(red). MiTF is expressed in parental and selected B16-GFP cells. Fewer B16-GFP cells are present in cultures with C2C12 cells. Nuclei were visualized by
Dapi staining (blue). Right panels: B16-GFP and selected B16-GFP melanoma cells grown with high density C2C12 or 10T1/2 fibroblasts and
immunostained for MiTF (red). MiTF expression is completely abrogated in parental and selected melanoma cells cultured with C2C12 cells plated at
high density. This effect is specific to muscle cells as it is not observed in high density 10T1/2 fibroblasts/B16-GFP co-cultures. Nuclei were
counterstained by Dapi (blue). Scale bar =50 mm.
doi:10.1371/journal.pone.0009299.g006
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obtained by enzymatic digestion of 18 days old embryos hind limb
muscles as previously described [99,100]. CHQ human muscle
cells were a kind gift of Dr. Butler-Browne [101].
B16-F10 melanoma cells and Luis Lung Carcinoma (LLC1)
were stably infected with a MoMuLV retroviral vector expressing
the GFP protein under the control of the CMV promoter. Cells
were sorted by Flow Cytometry to select for high GFP expression.
For coculture experiments, B16-GFP or LLC1-GFP tumor cells
were co-cultured with C2C12, 10T1/2, BNL CL.2, CHQ, at
ratios of 1/5, 1/10, 1/5,1/100, 1/400, 1/500 (tumor cells/non-
tumor cells) in GM. A ratio of 1/100 was used for all subsequent
experiments. To induce myogenic differentiation, after 3 days in
GM cells were switched to DMEM containing 2% (v/v) horse
serum (GIBCO) (Differentiation Medium, DM) for 5 to 9 days.
Primary mouse myoblasts were co-cultured with B16-GFP tumor
cells in a 1/500 ratio (tumor cells/myoblasts) for 3 days in GM,
and switched to DM for 4 days. For colony growth experiments
and MITF detection C2C12 or 10T1/2 cells were co-cultured
with B16-GFP tumor cells at a 1/400 ratio (tumor cells/non-
tumor cells) for 2 days in GM, and switched to DM for 2 days.
Immunostaining
Cells grown on 6,12 or 24 well plates and cryosections of mouse
hind limb muscles were fixed in 4% paraformaldehyde and stained
with antibodies against sarcomeric Myosin (MF20, Developmental
Hybridoma Bank of the University of Iowa), MyoD (Santa Cruz),
Laminin (Sigma), GFP (BD Pharmingen), and MiTF (Fisher
Scientific). Antibody binding was visualized by using biotin-
conjugated goat anti-mouse IgG followed by Cy3-conjugated
streptavidin (Jackson Immunoresearch), and Alexa488 or Cy3 -
conjugated conjugated goat anti-rabbit IgG (Molecular Probes).
Nuclei were counterstained with DAPI (Sigma). Photomicrographs
were obtained using a Leica inverted microscope (DMIL) a Leica
confocal microscope (DM2500 TCS SPE) and a Leica
DFC300FX camera. For detection of GFP+ myofibers, a narrow
range of emission wavelength (511 to 532 nm) was used to avoid
detection of autofluorescence [102].
RT-PCR
Cells were collected and RNA was extracted using RNeasy
minikit (Qiagen). RT was performed using SuperScriptII Reverse
Transcriptase (Invitrogen). Murine specific primers to detect
Desmin and MyoD transcripts were designed and a PCR was
performed. PCR conditions were 94uC for 4 min, followed by 30
cycles of 94uC for 1 min, 62uC for 1 min, and 72uC for 1 min.
Primers sequences used were as following: mDesF:59GAGG-
TTGTCAGCGAGGCTAC39; mDesR: 59CGATGACTT-
GAGCTGGGTTC39 mMyoDF: 59AGTGTCCTGCAGGCT-
CAAAC39; mMyoDR: 59TCT GCT CTT CCCTTCCCTCT39.
Quantitative Analysis
Melanin production was quantified by determining the number
of green cells showing black pigments of 10 randomly chosen fields
in 3 independent experiments.
Myogenic conversion of B16-GFP and LLC1-GFP cells was
quantified by determining the number of green myotubes
expressing either MyoD or MF20, and expressing this as a
percentage of the total number of myotubes per field (% of GFP+
myofibers). 10 randomly chosen fields in 3 independent experi-
ments were analyzed.
For colony growth experiments, the number of GFP positive
cells/colony was counted in triplicates. A total of 30 to 60 colonies
were analyzed per experimental condition.
Preparation and Collection of Culture Conditioned
Medium
C2C12 or 10T1/2 cells grown to confluence in GM, were
incubated in serum free DMEM (GIBCO) for 6,12,24,36 and
48 hours. At the end of the incubation period, the supernatant was
collected, centrifuged, filtered through a 0.22 mm filter (Millipore),
and frozen.
Cell Cycle Analysis
Cellswere cultured for 1 or 3 days in either CMC2C12 or CM10T1/2,
washed with PBS, fixed with 1% paraformaldehyde and resuspended
in PBS containing Propidium iodide (PI, 50 mg/ml, Molecular
Probes), RNaseA (0.1 mg/ml, Sigma) and Triton X-100 (0.05%,
Sigma). DNA content was analyzed by flow cytometry using a
FACScan (BectonDickinson, SanDi e go ,C A ) .T hep e r c e n t ag eofc e l l s
with sub-G0-G1 DNA content was counted as apoptotic cells. Values
represent the mean (6 SEM) from 3 independent experiments.
Tumor Suppression Assay
B16-F10-GFP cells were seeded in triplicates at a density of
12500 cells/cm
2 in 60 cm Falcon culture dishes and grown in
CMC2C12, CM10T1/2, or in DMEM for 4 days. Media was
changed once on day 3. After shifting them to GM for 2 days, cells
were trypsinized and submitted to a new round of selection as
described above. The selection process was repeated 3 times. The
number of surviving cells was determined at day 1, 3, and for each
selection round by counting the cells in 5 randomly chosen fields
from 3 independent experiments. Statistical analysis was per-
formed with Prism software using Student’s unpaired t-test.
Supporting Information
Text S1 Parlakian, et al. Material and methods.
Found at: doi:10.1371/journal.pone.0009299.s001 (0.03 MB
DOC)
Figure S1 Parlakian, et al. LLC1 carcinoma cells cultured with
skeletal muscle cells participate to the myogenic program. A)
Photomicrographs of GFP expressing Lewis Lung carcinoma cells
(LLC1-green) grown alone or in co-culture with myogenic cells
(C2C12), fibroblasts (10T1/2),or liver cells (BNL.CL2). We note the
elongated morphology of LLC1 carcinoma cells when co-cultured
with C2C12. Scale bar =100 mm. B) Representative photomicro-
graphs of GFP expressing LLC1 cells (green) grown and
differentiated in co-culture with C2C12 mouse myogenic cell line.
GFP labeled carcinoma cells fuse with the C2C12 cells forming
chimeric green myotubes, which arepositive for myosin heavy chain
(MF20, red) and the myogenic transcription factor MyoD (red).
Nuclei werevisualizedbyDAPIstaining (blue). Scale bare= 15 mm.
Found at: doi:10.1371/journal.pone.0009299.s002 (4.35 MB TIF)
Figure S2 Parlakian, et al. Apoptotic effect of the conditioned
media from C2C12 muscle cells on LLC1 carcinoma cells. Phase
contrast photomicrographs of LLC1 carcinoma cells cultured in
serum free conditioned media from 10T1/2 fibroblasts
(CM10T1/2) or in serum free conditioned media from muscle
cells (CMC2C12) for 3 days. After 3 days in CMC2C12, LLC1
carcinoma cells are less numerous and appear rounded and
clustered. Scale bar =50 mm.
Found at: doi:10.1371/journal.pone.0009299.s003 (0.49 MB TIF)
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